A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.
about
Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenovirusesPeptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerCyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusTRAIL in cancer therapy: present and future challenges.Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models.Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.Increasing the efficacy of oncolytic adenovirus vectorsTRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer.Gene therapy applications of viral vectors.Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAILGeneration of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.Virus-based therapies for colon cancer.Image-aided Suicide Gene Therapy Utilizing Multifunctional hTERT-targeting Adenovirus for Clinical Translation in Hepatocellular Carcinoma.Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapyReprogrammed viruses as cancer therapeutics: targeted, armed and shielded.In situ adenovirus vaccination engages T effector cells against cancerEpithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.Armed replicating adenoviruses for cancer virotherapy.Oncolytic virus therapy for prostate cancer.Oncolytic (replication-competent) adenoviruses as anticancer agents.Oncolytic viruses: a new class of immunotherapy drugs.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.Oncolytic Immunotherapy for Treatment of Cancer.Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatmentA helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette.Oncolytic viruses: adenoviruses.Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53.
P2860
Q33425253-EABD6B99-751E-4AFC-BCD6-13F3F3929ED2Q33584756-D34ADFAE-DE29-4453-9F32-1A52C3E613E1Q33641230-884ACA72-2E4B-4577-888A-EF3AD27934D8Q33690982-3617189A-0A05-4A5A-8A5A-BFB7161303ABQ34291312-E413C412-3AE1-4CFC-8AA3-BF3E252B2A21Q34293923-C8D2FE79-62DB-4AC4-95F9-0EDE5771FF44Q34313075-01DE5941-0221-494E-942E-59406176DEE1Q35261325-78CA4453-EFF1-4B06-9B9C-979A9CE713BAQ35647212-89C27F90-4439-42A6-806B-A9E41A041DD8Q35904004-7AC33A6E-1E7B-490D-BE45-E52164B87CABQ36209190-C02A067F-99D5-4AE7-882E-63917201CF95Q36306398-2D6A92E7-35D8-414C-8921-2788D3FA7A00Q36327069-A6A5C411-A10C-4A14-A337-84022BC82596Q36534195-89EC3DCE-AFB1-496D-9939-5B4668A61A05Q36539060-5B05F0C1-F123-44DB-A831-D2B5B85BD7E8Q37100291-C8E08EA7-3CBE-4290-9244-36B90ED269C8Q37104963-A901DBE0-4264-451C-9E3B-BCBEF0AAEFDCQ37191007-D63549A1-4802-4510-8400-668750103AD2Q37306292-83B070D3-A036-4B28-90A5-15C003FBD8E4Q37334241-8C4C68D3-BFEE-499F-A1CA-BFE87FAA70FAQ37386616-AB78928C-7DEA-4943-81FC-04FC2D17C1FEQ37615535-69EF5347-2980-451A-AA30-6A65A6748A45Q37687415-02D53EFB-F549-44A8-B831-5A937ECCE93DQ38577450-5A37FF87-48E3-413D-9E4D-F3021F0A2349Q38645128-DCDAE857-0B2A-429C-B9DE-DFE4737157C8Q38708598-A5ADC6CB-4F81-43A1-AD7A-C8541C95A1A1Q38848223-0B258CD1-2257-4268-A0AF-4EB36DEE853DQ38893420-0F0BB62C-C3DB-4449-9DF9-02354FA39985Q38918317-963F91A3-5CF8-4FFE-B826-11235E380392Q39020219-AD84B368-DD57-49DC-A4F2-B2D2046F17A2Q39107708-1B3CDD21-C072-4FCF-A0CB-943382D032A2Q39278465-CBB4D766-E4B1-42CD-B7A5-946E76E997D7Q39320579-DACD9CD3-6721-47F0-B344-5526F57644E3Q39432063-D84D0D01-9C56-45D9-9663-698875E0BD64Q39792478-1A3AE923-B4A1-4303-BCC6-54710A938F61Q40081527-3F1BCCBA-CD9B-48F6-9538-44999913C556Q40223632-A435DB6A-9EF1-4DF9-B9FB-20347FF33F16Q40250421-378E500F-A6AC-4CDC-AA9A-E0550A7D8034Q40262890-90665572-AD1B-4775-98D7-242A4AFB47ADQ40318210-6FC85B62-5756-418D-A2C0-87AFFD8523EB
P2860
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A tumor-targeted and condition ...... treatment of liver metastases.
@en
type
label
A tumor-targeted and condition ...... treatment of liver metastases.
@en
prefLabel
A tumor-targeted and condition ...... treatment of liver metastases.
@en
P2093
P1433
P1476
A tumor-targeted and condition ...... treatment of liver metastases
@en
P2093
André Lieber
Nancy Kiviat
Pavel Sova
Shaoheng Ni
Xiao-Wei Ren
P304
P356
10.1016/J.YMTHE.2003.12.008
P577
2004-04-01T00:00:00Z